PDPN and metastatic neoplasm: In addition, myoepithelial markers (e.g. p63, cytokeratin 14, and calponin) and endothelial markers (e.g., podoplanin and CD31) may be useful for the differential diagnosis of in situ-like architecture in the metastatic tumors [4, 5, 11].